APA (7th ed.) Citation

H, W., K, N., T, N., T, N., T, Y., K, T., . . . H, M. (2026). First-Line Therapy for Advanced Renal Cell Carcinoma: Score-Matched Analysis of Dual Combination Immunotherapy versus Combination of Tyrosine Kinase Inhibitors and Immunotherapy in the TOURS Multicenter Study. Targeted oncology, 21(3), 399. https://doi.org/10.1007/s11523-026-01219-y

Chicago Style (17th ed.) Citation

H, Watanabe, Nakane K, Nukaya T, Naiki T, Yasui T, Takahara K, Koie T, Inamoto T, and Miyake H. "First-Line Therapy for Advanced Renal Cell Carcinoma: Score-Matched Analysis of Dual Combination Immunotherapy Versus Combination of Tyrosine Kinase Inhibitors and Immunotherapy in the TOURS Multicenter Study." Targeted Oncology 21, no. 3 (2026): 399. https://doi.org/10.1007/s11523-026-01219-y.

MLA (9th ed.) Citation

H, Watanabe, et al. "First-Line Therapy for Advanced Renal Cell Carcinoma: Score-Matched Analysis of Dual Combination Immunotherapy Versus Combination of Tyrosine Kinase Inhibitors and Immunotherapy in the TOURS Multicenter Study." Targeted Oncology, vol. 21, no. 3, 2026, p. 399, https://doi.org/10.1007/s11523-026-01219-y.